Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808662 | 0.90 | CHRM2 (0.46) | CHRM2UTS2RSMN1; SMN2HTR1AADRA1D | |
| SCHEMBL6173269 | 0.84 | CHRM2 (0.70) | CHRM2UTS2RGBA1SMN1; SMN2HTR1A | |
| SCHEMBL14226176 | 0.83 | MAPT (0.44) | CHRM2UTS2RGBA1SMN1; SMN2HTR1A | |
| SCHEMBL9132120 | 0.82 | SMN1; SMN2 (0.47) | CHRM2SMN1; SMN2TSHRALDH1A1GAA | |
| SCHEMBL27982786 | 0.81 | TSHR (0.55) | CHRM2GBA1SMN1; SMN2HTR1AADRA1D | |
| SCHEMBL11496106 | 0.79 | CHRM2 (0.73) | CHRM2UTS2RGBA1SMN1; SMN2HTR1A | |
| SCHEMBL24277324 | 0.79 | CHRM2 (0.48) | CHRM2SMN1; SMN2HTR1AADRA1DADRA1A | |
| SCHEMBL24277459 | 0.79 | CHRM2 (0.48) | CHRM2SMN1; SMN2HTR1AADRA1DADRA1A | |
| SCHEMBL27973788 | 0.78 | NR3C1 (0.42) | UTS2RGBA1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL6933746 | 0.78 | CHRM2 (0.76) | CHRM2GBA1SMN1; SMN2HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4154884-A1 | ANTI-SARS-COV-2 DURG | Oncolys BioPharma, Inc. (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-2532652-B1 | THERAPEUTIC AGENT FOR HEPATITIS C | UNIV KAGOSHIMA (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2532652-B1 | THERAPEUTIC AGENT FOR HEPATITIS C | UNIV KAGOSHIMA (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-20120316342-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | ONCOLYS BIOPHARMA, INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316342-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | ONCOLYS BIOPHARMA, INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-2532652-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | Kagoshima University (JP) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532652-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | Kagoshima University (JP) | 2012-12-12 | — | — | EP | disclosed |
| CN-102812007-A | Therapeutic agent for hepatitis C | UNIV KAGOSHIMA | 2012-12-05 | — | — | CN | disclosed |
| WO-2011093483-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | 国立大学法人鹿児島大学 (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | CHRM2 692/4885UTS2R 2553/4885GBA1 1695/4885 |
| US-20120316342-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | HAVCR2, SLC10A1, FABP1 | CHRM2 4844/4885UTS2R 3458/4885GBA1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.